BTCY250321C5000
- 0.35
- 0.000.00%
Biotricity Newsroom
Biotricity Produces Largest Inventory in Its History to Meet Accelerated Demand
Biotricity Achieves Positive Free Cash Flow Milestone
HC Wainwright & Co. Reiterates Neutral on Biotricity
Biotricity Analyst Ratings
Biotricity Reports Revenue Growth Amidst Ongoing Losses
Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript Summary
Biotricity Reports Q2 EPS (7c) Vs. (44c) Last Year
Biotricity 2Q Rev $3.3M >BTCY
Biotricity | 10-Q: Q2 2025 Earnings Report
Biotricity (BTCY.US) will release its financial report after the market closes on November 15.
$Biotricity(BTCY.US)$ will release its financial report after the market closes on November 15, investors are requested to pay attention. How was the previous performance? $Biotricity(BTCY.US)$ revenue for 2025/Q1 was $3.201743 million, net income was -$-3.69452 million, and eps was -$0.49. Revenue for 2024/Q2 was $2.891297 million, net income was -$-3.69084 million, and eps was -$0.441. The above data was prepared in accordance with US GAAP accounting standards. Reminder from Futubull.
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th
SWK Holdings Provides Portfolio Update
Delisting of Securities of Gamer Pakistan Inc.; Biotricity, Inc.; Zalatoris II Acquisition Corp.; Warrantee Inc.; Spectaire Holdings, Inc.; Centogene N.V.; DZS Inc.; Corner Growth Acquisition Corp. 2; Collective Audience, Inc.; Grom Social Enterprises...
Biotricity Provides Updated Guidance for Earlier Than Expected Path to Profitability Due to Growing Revenues and Improving Margins
Biotricity Announces Inclusion as Supplier to Major Medical System
Biotricity Kicks off Another Pilot Program With a Major Hospital System That Services Over 800K Individuals
Biotricity Reports Continued Margin Improvement and Reduced Losses in Its First Quarter Fiscal Year 2025
Biotricity | 10-Q: Q1 2025 Earnings Report
Biotricity Announces Continued Margin Improvement Driven by Its Proprietary AI Cloud
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV